DermConsult
There’s a lot dermatology specialists need to consider when ensuring patients have healthy skin. And at a time when clinical research is increasingly defining skin conditions—and the practice of dermatology itself—as “more than skin deep,” turn to DermConsult.
In this special series, dermatology specialists share their expert advice on the diagnosis and treatment of a variety of skin conditions. They also explore the latest clinical research and their very own case studies, so you can rest assured you’ll have access to everything you need to know about the body’s largest organ.
16-30 of 113
When Alopecia Areata Signals More than Hair Loss
DermConsultWhen Alopecia Areata Signals More than Hair Loss
Light-Based Therapies for Alopecia: What’s Established and What’s Emerging
DermConsultLight-Based Therapies for Alopecia: What’s Established and What’s Emerging
Key Factors That Influence Psoriasis Diagnosis and Management
DermConsultKey Factors That Influence Psoriasis Diagnosis and Management
Exploring the Future of Psoriasis Treatment with Oral Agents
DermConsultExploring the Future of Psoriasis Treatment with Oral Agents
Rethinking the Routine: Moving from Topicals to Systemics in Psoriasis
DermConsultRethinking the Routine: Moving from Topicals to Systemics in Psoriasis
Targeting Psoriasis at the Source: New Evidence for Interferon Receptor Therapies
DermConsultTargeting Psoriasis at the Source: New Evidence for Interferon Receptor Therapies
- advertisement
Hitting the Target in Atopic Dermatitis: Interdisciplinary Team Training for Leveraging IL-13 Inhibitors to Address the Burden of Disease
CME/CEHitting the Target in Atopic Dermatitis: Interdisciplinary Team Training for Leveraging IL-13 Inhibitors to Address the Burden of Disease
Recognizing PSO-HS as a Distinct Subset with Shared Genetic Risk
DermConsultRecognizing PSO-HS as a Distinct Subset with Shared Genetic Risk
Unmasking Psoriasis in Skin of Color: Clinical Clues and Care Strategies
DermConsultUnmasking Psoriasis in Skin of Color: Clinical Clues and Care Strategies
TYK2 Inhibition with Zasocitinib Delivers Early Benefit Across PsA Domains
DermConsultTYK2 Inhibition with Zasocitinib Delivers Early Benefit Across PsA Domains
Rewriting the Rules of Psoriasis Severity: A Global Shift Toward Impact-Driven Care
FCDC Action CenterRewriting the Rules of Psoriasis Severity: A Global Shift Toward Impact-Driven Care
How Systemic Psoriasis Therapies Influence the Risk of New or Recurrent MACEs
FCDC Action CenterHow Systemic Psoriasis Therapies Influence the Risk of New or Recurrent MACEs
- advertisement
Improving Psoriatic Disease Care Through Dermatology–Rheumatology Clinics
FCDC Action CenterImproving Psoriatic Disease Care Through Dermatology–Rheumatology Clinics
Combination Therapy for Plaque Psoriasis: A Reappraisal of Cyclosporine and Acitretin
FCDC Action CenterCombination Therapy for Plaque Psoriasis: A Reappraisal of Cyclosporine and Acitretin
Understanding Sebopsoriasis: Navigating the Clinical Overlap of Dermatoses
DermConsultUnderstanding Sebopsoriasis: Navigating the Clinical Overlap of Dermatoses
